CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 332 target
Drug / intervention
Obinutuzumab +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05899621
NCT05899621N/ARecruitingUpdate OverdueUpdated 36mo ago · Completion was 12mo ago
Enrollment Stalled
Long Recruiting
Update Overdue
CompareCT.gov

A Real-world Study of the Efficacy and Safety of Obinutuzumab-based Therapy for Previously Untreated Follicular Lymphoma

Ruijin Hospital·observational·Posted Jun 12, 2023·Updated Jun 12, 2023

In Brief

An observational study evaluating Obinutuzumab, Lenalidomide, and 5 other interventions for Follicular Lymphoma. Currently recruiting, targeting 332 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

This study aims to observe and explore the efficacy and safety of obinutuzumab-based therapy for previously untreated follicular lymphoma

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsFollicular Lymphoma
CountriesChina
Collaborators--

Timeline

N/ARecruiting
2024202520262027
First PostedJun 12, 2023
Enrollment StartJun 1, 2023
Primary CompletionJun 30, 2025
Study CompletionJun 30, 2027
TodayJul 1, 2026
Enrollment to primary: 2.1 yearsPosted 3.1 years ago

Interventions

Obinutuzumabdrug

Obinutuzumab IV infusion will be administered as per the schedule specified in the respective arm.

Lenalidomidedrug

Lenalidomide PO will be administered as per the schedule specified in the respective arm.

Bendamustinedrug

Bendamustine IV infusion will be administered as per the schedule specified in the respective arm.

Cyclophosphamidedrug

Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.

Doxorubicindrug

Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.

Vincristinedrug

Vincristine IV infusion will be administered as per the schedule specified in the respective arm.

Prednisonedrug

Prednisone PO will be administered as per the schedule specified in the respective arm.